Opioids are not necessarily evil

June 01, 2016

Since 1999, the use of opioids for pain management has quadrupled in the USA, resulting in what is now well known as the 'opioid epidemic' -- too many Americans are now unnecessarily reliant on the drugs and opioid-related overdoses have rocketed.

Neurology Central is shining a light on this health crisis in an exclusive interview with Michael Schatman (Director of Research, U.S. Pain Foundation, CT, USA) discussing his recent thought-provoking editorial on the misuse of opioid dose calculation techniques in medical guidelines and the drivers of the opioid epidemic.

In the interview, Schatman discusses his recent paper 'The MEDD myth'. Despite the method of MEDD (morphine-equivalent daily dose) being confirmed as invalid late last year (Rennick et al), it has continued to be utilized as a dependent variable in pain research as well as in influential opioid prescribing guidelines, such as the 2015 Washington State Opioid Guidelines. "It's fraudulent, and that means that the guidelines based on this concept are fraudulent," Schatman comments. "We can't have a 'one size fits all' answer."

Schatman debates that these guidelines are a key cause of 'opiophobia', with doctors withdrawing opioid prescriptions where they are still needed and setting dosage limits that do not take into account differences in drug metabolism between patients. "There are many more patients in the US with chronic pain who don't respond to other treatments than there are prescription opioid addicts, yet the media are not particularly concerned with genuine data," explained Schatman.

Despite this, Schatman also considers the epidemic of opioid overdose and related deaths a substantial issue. Since 2007 the indiscriminate prescription of opioids in the USA has been flagged by Schatman personally. In the exclusive interview with Neurology Central, Schatman presents his thoughts on key drivers of the epidemic, including fraudulent marketing, financial motivations, and engrained cultural and political factors.

The discussion finishes on what needs to be done in order to control the overuse of opioids, focusing in on physician education and healthcare messaging: "What is being done, is scaring doctors by writing disingenuous opioid guidelines. What should be done, is what's being done in certain states, that is, mandatory continuing medical education in pain," Schatman comments. "The point is that opioids are not necessarily bad as long as there are careful risk mitigation strategies in place."
-end-
To read the interview in full go to: http://www.neurology-central.com/2016/05/26/opioids-are-not-necessarily-evil-michael-schatman/

Neurology Central will also be discussing the role of abuse deterrent formulations in the fight against opioid addiction in an upcoming free webinar. Registrants will learn more about strategies for preventing opioid abuse, common methods of abuse and the factors that must be taken into account for succesful in vivo studies of ADFs. Register here: http://www.neurology-central.com/2016/04/27/manipulation-of-abuse-deterrent-formulations-at-the-clinical-pharmacology-unit-altasciences/

About Neurology Central

Providing users with a go-to hub for all the latest news and insight into key topics and issues in the field, membership to Neurology Central is completely free of charge. The site features daily news, exclusive opinion pieces and interviews with key opinion leaders, as well as high-quality multimedia content, all of which is endorsed by an Expert Panel of researchers and clinicians from a range of different disciplines. Register online at http://www.neurology-central.com/register.

About Future Science Group

Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. FSG's portfolio includes two imprints, Future Science and Future Medicine. In addition to this core publishing business, FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine.

The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards. http://www.future-science-group.com

Future Science Group

Related Pain Articles from Brightsurf:

Pain researchers get a common language to describe pain
Pain researchers around the world have agreed to classify pain in the mouth, jaw and face according to the same system.

It's not just a pain in the head -- facial pain can be a symptom of headaches too
A new study finds that up to 10% of people with headaches also have facial pain.

New opioid speeds up recovery without increasing pain sensitivity or risk of chronic pain
A new type of non-addictive opioid developed by researchers at Tulane University and the Southeast Louisiana Veterans Health Care System accelerates recovery time from pain compared to morphine without increasing pain sensitivity, according to a new study published in the Journal of Neuroinflammation.

The insular cortex processes pain and drives learning from pain
Neuroscientists at EPFL have discovered an area of the brain, the insular cortex, that processes painful experiences and thereby drives learning from aversive events.

Pain, pain go away: new tools improve students' experience of school-based vaccines
Researchers at the University of Toronto and The Hospital for Sick Children (SickKids) have teamed up with educators, public health practitioners and grade seven students in Ontario to develop and implement a new approach to delivering school-based vaccines that improves student experience.

Pain sensitization increases risk of persistent knee pain
Becoming more sensitive to pain, or pain sensitization, is an important risk factor for developing persistent knee pain in osteoarthritis (OA), according to a new study by researchers from the Université de Montréal (UdeM) School of Rehabilitation and Hôpital Maisonneuve Rosemont Research Centre (CRHMR) in collaboration with researchers at Boston University School of Medicine (BUSM).

Becoming more sensitive to pain increases the risk of knee pain not going away
A new study by researchers in Montreal and Boston looks at the role that pain plays in osteoarthritis, a disease that affects over 300 million adults worldwide.

Pain disruption therapy treats source of chronic back pain
People with treatment-resistant back pain may get significant and lasting relief with dorsal root ganglion (DRG) stimulation therapy, an innovative treatment that short-circuits pain, suggests a study presented at the ANESTHESIOLOGY® 2018 annual meeting.

Sugar pills relieve pain for chronic pain patients
Someday doctors may prescribe sugar pills for certain chronic pain patients based on their brain anatomy and psychology.

Peripheral nerve block provides some with long-lasting pain relief for severe facial pain
A new study has shown that use of peripheral nerve blocks in the treatment of Trigeminal Neuralgia (TGN) may produce long-term pain relief.

Read More: Pain News and Pain Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.